Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Siminiak, T.
Right arrow Articles by Serruys, P. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Siminiak, T.
Right arrow Articles by Serruys, P. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury

Tomasz Siminiak1,*, Emanuele Meliga2, Olga Jerzykowska1 and Patrick W. Serruys2

1 Department of Cardiology, Poznan University of Medical Sciences, Cardiac and Rehabilitation Hospital, ul. Sanatoryjna 34, 64-600 Kowanówko k/Obornik Wlkp, Poland
2 Department of Cardiology, Thorax Center, Erasmus Medical Center, Rotterdam, The Netherlands

* Corresponding author. Tel: +48 602217202; fax: +48 612977500. E-mail address: tomasz.siminiak{at}usoms.poznan.pl

Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.

Key Words: Heart failure • Myoblasts • Cell transplantation • Catheter systems


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.